DDX56 and cancer: Therefore, we analyzed pan-cancer single-cell RNA-seq data using the TISCH database and observed that DDX56 was mainly expressed in tumor cells rather than immune cells, stromal cells, and others (Figure 1C), indicating the potential of DDX56 as a tumor biomarker and drug target.